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Abstract. – OBJECTIVE: The aim of this study 
was to evaluate the reparative role of hyaluronic 
acid in acute rhinosinusitis (ARS).
PATIENTS AND METHODS: 48 patients affect-
ed by ARS were submitted to nasal endoscopy, na-
sal cytology, mucociliary transport evaluation 
(MCTt) and visual analogue scale questionnaire 
(VAS) at T0, after 14-18 days (T1) and after 30-35 
days (T2). The patients were randomized into two 
groups, A and B, and received Levofloxacin and 
Prednisone. Moreover, using a nebulizer ampoule 
for nasal douche, Group A received high molecular 
weight Sodium Hyaluronate (3%) plus saline solu-
tion (NaCl 0.9%) twice a day for 30 days; Group B 
received saline solution twice a day for 30 days.
RESULTS: At T0 only the VAS score showed dif-
ferences regarding nasal discharge and post-nasal 
drip. At T1, in Group A MCTt and the number of bacte-
ria were significantly lower than in Group B. The VAS 
score showed improvement in Group A. At T2 in 
Group A, MCTt and number of neutrophils were sig-
nificantly lower than in Group B. The VAS score 
showed statistically significant differences be-
tween the two groups regarding nasal discharge.
CONCLUSIONS: In ARS patients sodium hyal-
uronate plus saline solution significantly im-
proved symptoms, MCT time and reduced neutro-
phil count on nasal cytology.
Key Words
Rhinosinusitis, Nasal cytology, Mucociliary trans-
port, Hyaluronic acid, Visual analogue scale question-
naire.
Introduction
Acute rhinosinusitis (ARS) is a highly common 
condition whose incidence is steadily increasing. 
Its incidence varies among different studies from 
6% to 15%, but its real impact is probably higher 
because it represents one of the major causes of 
primary care consultation. Therefore, ARS pre-
sents a considerable socio-economic burden and 
may be related to a negative impact on quality of 
life, especially for the recurring form1,2. 
In most cases, ARS is sustained by a viral ae-
tiology (rhinoviruses, coronaviruses) and, gener-
ally, bacterial infection occurs only secondarily. 
The main bacterial pathogens identified in ARS 
are Streptococcus pneumoniae, Haemophilus in-
fluenza and Moraxella catarrhalis. In a minority 
of cases, Streptococcus pyogenes, Staphylococ-
cus aureus, Gram-negative bacilli, and oral an-
aerobes may also be identified3-5. 
According to EPOS criteria, ARS is defined as 
a simultaneous inflammation of the mucosa of both 
the nose and paranasal sinuses: the obstruction of 
the sinus ostia caused by edema and congestion 
of the rhinosinusal mucosa and the alteration of 
mucociliary transport induced by impairment of 
the cilia, determine stagnation of secretions and 
bacterial proliferation. Signs and symptoms char-
acteristic of ARS are nasal blockage, congestion or 
stuffiness, nasal discharge or postnasal drip, often 
mucopurulent, facial pain or pressure, headache, 
and reduction/loss of smell (for <4 weeks)2.
The goal of therapy is to reduce the severity 
and duration of symptoms and prevent complica-
tions. In addition to antibiotic and corticosteroid 
therapy, adjunctive thera pies such as antihista-
mines, intranasal corticosteroids, decongestants, 
saline irrigation, mucolytic and phytotherapeutic 
agents have been investigated6-14. To our knowl-
edge, of all these substances, the most widely used 
as adjuvant treatment is still the saline solution7,8.
Recently, studies have evaluated the role of hy-
aluronic acid in the inflammation of the nasal mu-
cosa15-17. There are two forms of hyaluronic acid, 
based on molecular weight. High molecular weight 
hyaluronic acid (>103 kDa) shows higher viscosity, 
longer resident time and higher biocompatibility 
than the lower one (<103 kDa)15. The physiological 
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role of high molecular weight hyaluronic acid can 
suppress immune system function and limit in-
flammatory response16,17. During an inflammatory 
process, the free radicals and enzymes, produced 
during this status, lead to a fragmentation of hya-
luronic acid into low molecular weight molecules 
that display proinflammatory effects18. Recently, 
high molecular weight hyaluronic acid has been 
introduced into clinical practice for the manage-
ment of sinus and nasal pathologies. In fact, some 
studies have demonstrated that it plays an anti-in-
flammatory and reparative role in the treatment 
of chronic rhinosinusitis, minimizing symptoms 
and preventing exacerbations19,20. Moreover, it was 
employed in patients undergoing functional en-
doscopic sinus surgery for rhinosinusal remodel-
ling21,22. 
The aim of this study was to compare the 
adjuvant therapeutic value of high molecular wei-
ght hyaluronic acid in a group of adult patients 
suffering from ARS under treatment with anti-
biotics, systemic steroid treatment and irrigation 
with saline solution as local therapy. The thera-
peutic effect of hyaluronic acid was evaluated 
by analyzing nasal cytological properties and 
mucous ciliary clearance.
Patients and Methods
From December 2014 to April 2015, in the De-
partment of Sense Organs of Sapienza University 
in Rome, 48 consecutive adult patients with acute 
bacterial rhinosinusitis symptoms, according to 
the above-reported guidelines2, were prospectively 
enrolled in the study. Ethics approval has been 
obtained by our IRB of the Sapienza University.
All enrolled patients signed a written infor-
med consent prior to entering the study and were 
investigated at first time evaluation (T0), after 
14-18 days (T1) and after 30-35 days (T2).
All patients underwent to: 
  •  Clinical records collection and ENT examina-
tion with nasal endoscopy (2.7 mm 0-degree 
rigid endoscope);
  •  CT scan of nasal and sinusal structures (axial, 
coronal and sagittal projections) performed at T0 
time in order to confirm the diagnosis of ARS; 
  •  Nasal cytology: a scraping of the nasal mucosa 
on the middle third of the inferior turbinate 
was performed. After sampling, the material 
was laid on a microscope slide, fixed for air 
dry and stained by the May-Grunwald-Giem-
sa method. The smear was observed under a 
common light microscope equipped with 1000 
x objective. For analyzing the rhino cytogram, 
we performed with a reading for fields (not 
less than 50), in order to observe the cellular 
elements that composed the nasal mucosa (eo-
sinophils, mast cells, neutrophils, lymphocytes, 
bacteria, spores, biofilms and so on). To calcu-
late the percentage of each cellular element, 
semi-quantitative grading counts of each cell 
type, according to the previously published 
studies, were performed (grade 1+: occasional 
groups, grade 2+: moderate number, grade 3+: 
easily visible, grade 4+: elevated number)23-26. 
This model of grading for nasal cytology that 
we used26 is well represented in Table I.
  •  Nasal MCT-time was determined by applying 
some charcoal powder to the head of the 
inferior turbinate using a cotton stick. The 
subsequent appearance of blackish colouring 
in the oro-pharynx (normal values= 12 min ± 
3)27-30 was evaluated by direct pharyngoscopy. 
  •  Visual Analog Scale (VAS): a questionnai-
re was issued for subjective assessment of 
symptoms such as nasal obstruction, nasal 
discharge, post-nasal drip, facial pain (0=ab-
sent; 1=mild; 2=moderate; 3=severe) and ol-
factory perception (0=normal; 1=decreased; 
2=absent)31,33. 
Patients were enrolled with a randomized se-
lection into Group A and Group B. All patients 
received antibiotic and systemic steroid therapy 
(Levofloxacin, 500 mg for 10 days, and Predni-
sone, 50 mg for 8 days, 25 mg for 4 days and 12, 
5 mg for 4 days). Moreover, Group A received hi-
gh molecular weight (800.000-1.000.000 Daltons) 
sodium hyaluronate (3%) plus saline solution (3 
mL sodium chloride-NaCl- 0.9%) twice a day 
for 30 days using a nebulizer ampoule for nasal 
douche (Rinowash, Air Liquide Medical System 
Spa, Bovezzo, Brescia, Italy). Group B received 
saline solution (6 mL sodium chloride-NaCl- 
0.9%) twice a day for 30 days using a nebulizer 
ampoule for nasal douche.
All the patients enrolled completed all the 
evaluations and no episodes of drug intolerance 
occurred.
Statistical analysis was performed by compa-
ring the data of Group A and Group B at T0, T1 
and T2. The Chi-square test was used for catego-
rical variables; while the non-parametric Wilcoxon 
Mann-Whitney test was used for continuous va-
riables. Continuous variables were presented as 
median and interquartile range (IQR). All data 
were analyzed using Stata SE 10.1 System.
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Results
Both groups were composed of 24 patients: 
  •  Group A, 12 males and 12 females, mean age 
of 44 years (38-50 IQR); 
  •  Group B, 14 males and 10 females, mean age 
of 43 years (35-55 IQR). 
There were no statistical differences between the 
two groups regarding demographic data (Table II).
CT scans showed rhinosinusitis and conge-
stion involving the ostio-meatal complex in 100% 
of patients, ethmoidal, ethmoido-maxillar and 
fronto-ethmoidal rhinosinusitis in 15%, 65% and 
20% of cases respectively in Group A and in 
25%, 45% and 30% respectively in Group B. 
At the beginning of treatment (T0), there 
were no statistical differences between the two 
groups regarding cytological and MCTt data, 
but the self-assessment questionnaire (VAS) 
score showed statistically significant differen-
ces between the two groups regarding nasal di-
scharge (p=0.010) and post-nasal drip (p=0.02) 
(Table III). This result represented an unexpected 
finding at this moment of study (T0), conside-
ring that patients were randomized into the two 
different groups and did not begin any adjuvant 
therapies. So, it was a not relevant result at this 
moment of examination for the aim of the study.
After 14-18 days’ treatment (T1), MCTt was 
significantly lower in Group A than in Group B: 
Table I. Description and semiquantitative grading for Nasal Citology reporting.
*CCP: ciliocytophtoria; MN: multinucleation.
 Description Grading* 
Epithelial ciliated cells Normal N
 Abnormal A ( CCP/MN)
Mucinous cells None 0
 Occasional 1+
 Moderate number 2
 Large number 3+
 Covering the entire field 4+
Neutrophils and Eosinophils None 0
 Occasional ½+
 Few scattered cells, small clumps 1+
 Moderate number, large clumps 2+
 Large clumps not covering the field 3+
 Clumps covering entire field 4+
Basophils (Mast cells) None 0
 Occasional ½+
 Few scattered cells, small clumps 1+
 Moderate number, large clumps 2+
 Large clumps not covering the field 3+
 Upt to 25 per an X100 field 4+
Eosinophil/Mast cell degranulation None observed 0
 Occasional granules 1+
 Moderate number of granules 2+
 Many granules easily seen 3+
 Massive degranulation, entire field 4+
Bacteria and spores None observed 0
 Occasional clumps 1+
 Moderate number 2+
 Many cells easily seen 3+
 Bacteria/spores over the entire field 4+
Table II. Demographic data.
  Group A (n=24) Group B (n=24) p  
    
Male, n (%) 12 (50.0%) 14 (58.3%) 0.562
Age (years), median (IQR) 44 (38-50) 43 (35-55) 0.975
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the median value was 15 minutes (IQR: 12.5-
15) in Group A and 20 minutes (IQR: 15-20) in 
Group B (p=0.003) (Table IV).
Cytological evaluation yielded a lower number 
of bacteria in Group A (Figure 1). Although the 
median distribution was the same in both groups, 
there was a statistically significant difference 
(p=0.019). There were no statistical differences 
between the two groups regarding other cytolo-
gical evaluations, even those regarding biofilm 
and mycetes distribution (Figure 4) (Table IV).
The VAS score showed statistically significant 
differences between the two groups, in particular 
for smell (p=0.018), nasal obstruction (p<0.001) 
and nasal discharge (p=0.006) that had a lower 
incidence in group A (Table IV).
After 30 days’ treatment (T2), MCTt was 
significantly lower in Group A than in Group B: 
the median value was 15 minutes in both groups 
but there was a different distribution of values 
(IQR: 10-15 in Group A, IQR: 15-15 in Group B) 
(p=0.021) (Table V). 
At T2 cytological evaluation, we found a lower 
number of neutrophils in Group A (p<0.001) (Fi-
gures 2, 3) There were no statistical differences 
between the two groups regarding other cytolo-
gical evaluations (Table V).
The VAS score showed a statistically signifi-
cant difference between the two groups for nasal 
discharge alone that had a lower prevalence in 
Group A (p=0.040, same median, different di-
stribution) (Table V).
Discussion
During ARS, the inflammatory response of 
the nasal mucosa results in edema, mucous pro-
duction and fluid extravasation. In addition to 
antibiotic and corticosteroid therapy, adjunctive 
Table III. Baseline characteristics of patients (T0).
  Group A (n=24) Group B (n=24) p  
MCTt, median (IQR) 20 (20-25) 20 (20-25) 0.853
Cytology   
    Neutrophils, median (IQR) 3 (2-3) 2 (1-3) 0.252
    Eosinophils, median (IQR) 0 (0-1) 0 (0-0) 0.089
    Mast-cells, median (IQR) 0 (0-0) 0 (0-0) 0.686
    Bacteria, median (IQR) 2 (1-2) 1.5 (1-2.5) 0.947
    Biofilm, n (%) 8 (33.3%) 8 (33.3%) 1.000
    Mycetes, n (%) 3 (12.5%) 2 (8.3%) 0.637
VAS   
    Smell 0-2 2 (1-2) 1.5 (1-2) 0.388
    Obstruction 0-3 2 (1.5-2) 1.5 (1-2) 0.142
    Discharge 0-3 2 (2-3) 1 (1-2) 0.010
    Post-nasal drip 0-3 1 (0-2) 0 (0-1) 0.022
    Facial pain 1 (1-2) 1 (1-2) 0.274
Table IV. Comparing data after 14-18 days’ treatment (T1).
  Group A (n=24) Group B (n=24) p  
MCTt, median (IQR) 15 (12.5-15) 20 (15-20) 0.003
Cytology   
    Neutrophils, median (IQR) 1 (1-1) 1 (0-1) 0.282
    Eosinophils, median (IQR) 0 (0-0) 0 (0-0) 0.416
    Mast-cells, median (IQR) 0 (0-0) 0 (0-0) 1.000
    Bacteria, median (IQR) 1 (0-1) 1 (1-1.5) 0.019
    Biofilm, n (%) 6 (25.0%) 3 (12.5%) 0.267
    Mycetes, n (%) 2 (8.3%) 1 (4.2%) 0.551
VAS   
    Smell 0-2 0 (0-1) 1 (1-1) 0.018
    Obstruction 0-3 0 (0-0.5) 1 (1-1) <0.001
    Discharge 0-3 0.5 (0-1) 1 (1-2) 0.006
    Post-nasal drip 0-3 0 (0-0) 0 (0-0) 0.714
    Facial pain 0 (0-1) 0 (0-1) 0.700
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thera pies have been investigated to reduce the 
severity and duration of symptoms and prevent 
complications. Decongestant, nasal irrigation 
with saline and intranasal corticosteroids may 
be used as a support therapy to reduce mucosal 
edema, improve mucociliary clearance and fa-
cilitate aeration and drainage during acute epi-
sodes. Even if there are not enough studies to 
support the action of these drugs when used 
in association with antibiotic and corticosteroid 
therapy, they may provide additional benefits by 
alleviating symptoms6-12. Antihistaminic therapy 
is often used but, according to a Cochrane review, 
should be used for symp tomatic relief of acute si-
nusitis only in patients with a history of allergy13. 
During recent years, phytotherapeutic agents and 
herbal compounds have also been introduced 
but further studies and meta-analysis are needed 
for understanding their real effectiveness in the 
treatment of ARS2,14. In accordance with the abo-
ve-reported data, the substance that is still widely 
used as an adjuvant therapy in ARS patients is 
the saline solution7,8. However, throughout the last 
few years, several studies have documented the 
effectiveness of hyaluronic acid in the prevention 
of exacerbations of chronic rhinosinusitis and 
in post-operative tissue repair after rhinosinusal 
surgery20-22.
Hyaluronic acid is a large non-sulphated 
glycosaminoglycan with a high molecular wei-
ght and is the main component of many organs 
and tissues, such as connective tissue, skin, and 
synovial fluid. The extracellular matrices of the 
respiratory epithelial cells and gland serous cells 
in the mucosa of upper airways and tracheobron-
chial tracts is made up of a three-dimensional 
plot of hyaluronic acid, chondroitin sulphate and 
heparin sulphate. This structure is essential for 
ciliary clearance and for the regulation of enzy-
matic activity, which are essential for maintai-
ning the homeostasis on the apical surface34,35. 
The presence of tissue damage or inflammation 
activates the coordinated action of platelet cells, 
neutrophils, and monocytes that, in turn, triggers 
the development of a network made up of signals 
responsible for automatization and consolidation 
Figure 1. Bacterial biofilm (arrows) (May-Grumwald-Gi-
emsa, 1000X).
Figure 2. Acute Rhinosinusitis: clear evidence of large 
distribution of neutrophils (arrow) (May-Grumwald-Giem-
sa, 1000X).
Figure 3. Neutrophils and Bacteria (arrow and arrow head) 
(May-Grumwald-Giemsa, 1000X).
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of tissue response. The free radicals and enzy-
mes, produced during inflammatory status, lead 
to a fragmentation of hyaluronic acid into low 
molecular weight molecules that act as proinflam-
matory mediators, promoting and supporting the 
immune response18. Therefore, the high molecu-
lar weight of hyaluronic acid molecules suppres-
ses the immune system function and limits the 
inflammatory response, thus promoting tissue 
proliferation and tissue remodelling, and modula-
ting cell migration and chemotaxis, angiogenesis 
and inflammatory responses16,17. 
In our study, we added sodium hyaluronate 
(3%) plus saline solution (3 mL-NaCl- 0.9%) using 
a nebulizer ampoule for nasal douche to antibiotic 
and steroid therapy and to investigate its effect in 
all enrolled patients after 14 (T1) and 30 (T2) days’ 
treatment. All patients underwent MCT time eva-
luation, nasal cytology performed by scraping of 
the nasal mucosa on the middle third of the inferior 
turbinate. They also filled out a VAS questionnai-
re for subjective assessment of nasal obstruction, 
nasal discharge, post-nasal drip, facial pain and ol-
factory perception31-33. Regarding cytological eva-
luation, there were no statistical differences betwe-
en the two groups at first evaluation (T0); after 14 
days therapy (T1), a lower number of bacteria were 
observed in Group A; after 1 month (T2) there was 
a significant decrease in the number of neutrophils 
(p<0.001). In addition, we observed a moderate 
improvement of clinical parameters and of MCTt 
at T1 and T2 in Group A. These data showed that 
in Group A recovery of the physiological function 
of the nasal mucosa was faster, as demonstrated 
by normal MCT-time values at T2. The use of 
hyaluronic acid as supporting therapy in ARS al-
lowed a faster recovery of mucociliary clearance, 
modulation of inflammatory responses and tissue 
Figure 4. Fungal spores (arrow) (May-Grum-
wald-Giemsa 1000X).
Table V. Comparing data after 30 days’ treatment (T2).
  Group A (n=24) Group B (n=24) p  
MCTt, median (IQR) 15 (10-15) 15 (15-15) 0.021
Cytology   
    Neutrophils, median (IQR) 0 (0-1) 1 (0.5-1) <0.001
    Eosinophils, median (IQR) 0 (0-0) 0 (0-0) 0.686
    Mast-cells, median (IQR) 0 (0-0) 0 (0-0) 0.530
    Bacteria, median (IQR) 0 (0-0) 0 (0-1) 0.059
    Biofilm, n (%) 2 (8.3%) 0 (0%) 0.149
    Mycetes, n (%) 0 (0%) 1 (4.2%) 0.312
VAS   
    Smell 0-2 0 (0-0) 0 (0-0) 1.000
    Obstruction 0-3 0 (0-0) 0 (0-1) 0.335
    Discharge 0-3 0 (0-0) 0 (0-1) 0.040
    Post-nasal drip 0-3 0 (0-0) 0 (0-0.5) 0.125
    Facial pain 0 (0-0) 0 (0-0) 0.388
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proliferation and remodelling. According to other 
studies, the inflammatory modulation effect mani-
fests as a reduction in the bacterial count after 14 
days and in the neutrophil count after one month 
of treatment. It is also confirmed by the subjecti-
ve improvement of some symptoms, after just 14 
days of therapy22, such as nasal obstruction, smell 
and nasal discharge in Group A. After 30 days of 
therapy (T2) results showed a persistent improve-
ment of nasal discharge. This is an important data 
that suggests the possibility of increasing patient 
compliance by using adjunctive therapy.
Conclusions
Our study demonstrated the effectiveness of 
hyaluronic acid as a support therapy to systemic 
antibiotic and corticosteroid treatment in patients 
with acute rhinosinusitis. Treatment with sodium 
hyaluronate (3%) plus saline solution brought 
about a significant improvement in global asses-
sment of subjective symptoms, normalization of 
MCT time and reduction of neutrophil count on 
nasal cytology. ARS represents a considerable 
socio-economic burden and may also have a ne-
gative impact on the quality of life, especially in 
the recurring forms. Therefore, sodium hyaluro-
nate could play an important role in the treatment 
of acute rhinosinusitis by favouring tissue repair, 
restoring mucosal function and reducing the se-
verity and duration of symptoms.
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